{
  "docId": "019de073-7a8f-7069-abd7-4f5a253312a5",
  "docSlug": "7534f8dddd85d538a9efc95a5aebf002",
  "documentTitle": "Aquestive Therapeutics | Results Presentation Deck | 14 slides",
  "authorId": "aquestive-therapeutics",
  "authorName": "Aquestive Therapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 3,
  "pageCount": 14,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Comparison of Tmax metrics and safety profiles for single vs repeat dosing.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7a8f-7069-abd7-4f5a253312a5/3",
  "deckHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5",
  "deckJsonHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5.json",
  "deckAnchorHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.53,
        "y": 0.395
      },
      "kind": "list",
      "text": "Demonstrated successful absorption of a second dose of AQST-109 in all subjects; Second dose had an observed median Tmax of 18 minutes; No severe or serious safety or tolerability events were observed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f3cb0fb-5dd0-4326-8981-67009b1296b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.12,
        "y": 0.395
      },
      "kind": "list",
      "text": "Confirmation of 12-minute median time to maximum concentration (Tmax); Faster observed median Tmax than either EpiPen (22 minutes) or 0.3mg IM injection (45 minutes); Safety profile in line with previous studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f56e23a5-fc8b-42e5-af6f-f5f8be0d533a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "1. Second dose administered 10 minutes after the first.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca48527c-eb0c-4ba0-ba7a-791ae84a315b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.07,
        "y": 0.19
      },
      "kind": "title",
      "text": "EPIPHAST II: Trial Results Key Takeaways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea0e5b97-09f2-4f4e-aca5-284e5bdfbb65",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 3,
      "beatId": "fd64535f-8805-4be0-ab9c-f0396589752f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document provides relief through presentation of EPIPHAST II trial results, including key takeaways and data, on slides 3-13",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}